Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, ...

An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on ...

A new study suggests Paxlovid may not reduce the risk of covid-19 hospitalizations and all-cause deaths in vaccinated adults ...

Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ...

“I think that needs to be part of the conversation.” A spokesperson for Pfizer, which makes Paxlovid, said the company stands ...

Medicare beneficiaries can get Paxlovid for free through the U.S. Government Patient Assistance Program (USG PAP) until December 31, 2025. Read more.

That’s very different from the results that Paxlovid’s maker, Pfizer, first reported in 2022. In that study, Pfizer found that the drug reduced hospitalizations and deaths from COVID-19 by 89% ...

Pfizer has revealed what it will charge for a five-day course of its oral antiviral Paxlovid for COVID-19 when it starts to see it on the commercial market later this year. The drugmaker has set a ...

Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research. The study questions the assumption that Paxlovid's ...

The U.S. Government Patient Assistance Program (USG PAP), operated by Pfizer, will provide eligible Medicare beneficiaries with free Paxlovid access until December 31, 2025. This program is also ...

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.